

¹⁸F-Fluoride and ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography After Transient Ischemic Attack or Minor Ischemic Stroke Case–Control Study

Alex T. Vesey, MD; William S. A. Jenkins, MD; Agnese Irkle, PhD; Alastair Moss, MD; Greg Sng, MD; Rachael O. Forsythe, MD; Tim Clark, MSc; Gemma Roberts, MSc; Alison Fletcher, PhD; Christophe Lucatelli, PhD; James H. F. Rudd, MD, PhD; Anthony P. Davenport, PhD; Nicholas L. Mills, MD, PhD; Rustam Al-Shahi Salman, MA, PhD; Martin Dennis, MD, PhD; William N. Whiteley, MD, PhD; Edwin J. R. van Beek, MD, PhD; Marc R. Dweck, MD PhD; David E. Newby, MD, PhD, DSc

Background—Combined positron emission tomography (PET) and computed tomography (CT) can assess both anatomy and biology of carotid atherosclerosis. We sought to assess whether ¹⁸F-fluoride or ¹⁸F-fluorodeoxyglucose can identify culprit and high-risk carotid plaque.

Methods and Results—We performed ¹⁸F-fluoride and ¹⁸F-fluorodeoxyglucose PET/CT in 26 patients after recent transient ischemic attack or minor ischemic stroke: 18 patients with culprit carotid stenosis awaiting carotid endarterectomy and 8 controls without culprit carotid atheroma. We compared standardized uptake values in the clinically adjudicated culprit to the contralateral asymptomatic artery, and assessed the relationship between radiotracer uptake and plaque phenotype or predicted cardiovascular risk (ASSIGN score [Assessing Cardiovascular Risk Using SIGN Guidelines to Assign Preventive Treatment]). We also performed micro PET/CT and histological analysis of excised plaque. On histological and micro PET/CT analysis, ¹⁸F-fluoride selectively highlighted microcalcification. Carotid ¹⁸F-fluoride uptake was increased in clinically adjudicated culprit plaques compared with asymptomatic contralateral plaques (\log_{10} standardized uptake value_{mean} 0.29 ± 0.10 versus 0.23 ± 0.11 , $P=0.001$) and compared with control patients (\log_{10} standardized uptake value_{mean} 0.29 ± 0.10 versus 0.12 ± 0.11 , $P=0.001$). ¹⁸F-Fluoride uptake correlated with high-risk plaque features (remodeling index [$r=0.53$, $P=0.003$], plaque burden [$r=0.51$, $P=0.004$]), and predicted cardiovascular risk [$r=0.65$, $P=0.002$]). Carotid ¹⁸F-fluorodeoxyglucose uptake appeared to be increased in 7 of 16 culprit plaques, but no overall differences in uptake were observed in culprit versus contralateral plaques or control patients. However, ¹⁸F-fluorodeoxyglucose did correlate with predicted cardiovascular risk ($r=0.53$, $P=0.019$), but not with plaque phenotype.

Conclusions—¹⁸F-Fluoride PET/CT highlights culprit and phenotypically high-risk carotid plaque. This has the potential to improve risk stratification and selection of patients who may benefit from intervention. (*Circ Cardiovasc Imaging*. 2017;10:e004976. DOI: 10.1161/CIRCIMAGING.116.004976.)

Key Words: carotid stenosis ■ fluorides ■ inflammation ■ nuclear medicine ■ phenotype ■ stroke

Although carotid endarterectomy reduces risk of ipsilateral stroke in people with symptomatic carotid artery stenosis, the number needed to treat to prevent one stroke is large,^{1,2} especially in asymptomatic stenosis.³ Furthermore, the pathological event that leads to cerebral thromboembolism (atherosclerotic plaque rupture) is not necessarily correlated with luminal stenosis severity.⁴ Other pathological

See Editorial by Tawakol et al
See Clinical Perspective

features, such as inflammation, cell death, and microcalcification, are important in driving both plaque formation and instability.^{5–7} New imaging biomarkers of these processes are therefore needed to improve risk stratification and clinical

Received May 2, 2016; accepted January 12, 2017.

From the BHF Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (A.T.V., W.S.A.J., A.M., G.S., R.O.F., N.L.M., E.J.R.v.B., M.R.D., D.E.N.); Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, United Kingdom (A.I., J.R., A.P.D.); and Clinical Research Imaging Centre (T.C., G.R., A.F., C.L., E.J.R.v.B., M.R.D., D.E.N.) and Centre for Clinical Brain Sciences (R.A.-S.S., M.D., W.W.), University of Edinburgh, United Kingdom.

The Data Supplement is available at <http://circimaging.ahajournals.org/lookup/suppl/doi:10.1161/CIRCIMAGING.116.004976/-/DC1>.

Correspondence to Alex T. Vesey, MD, Centre for Cardiovascular Science, University of Edinburgh, Room SU 305, Chancellor's Bldg., 49 Little France Crescent, Edinburgh, EH16 4SB, United Kingdom. E-mail: avesey@staffmail.ed.ac.uk

© 2017 The Authors. *Circulation: Cardiovascular Imaging* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Circ Cardiovasc Imaging is available at <http://circimaging.ahajournals.org>

DOI: 10.1161/CIRCIMAGING.116.004976

decision-making. Such biomarkers could also assess the response of plaque biology to novel pharmacological interventions and provide a way of identifying culprit lesions in patients with multiple plaques.

Hybrid positron emission tomography and computed tomography (PET/CT) is a molecular imaging modality that has high sensitivity for noninvasive in vivo detection of radio-labeled biomolecules tuned to a variety of pathophysiological processes. In carotid atherosclerosis imaging, the most widely used tracer has been ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG)^{8–14}. Recently, we have described another radiotracer, ¹⁸F-fluoride, in atherosclerosis imaging.^{15,16} We^{15–18} and others^{19–23} have shown that this tracer has major potential in cardiovascular disease. ¹⁸F-Fluoride can highlight culprit plaque in patients after myocardial infarction and high-risk plaques in patients with apparently stable coronary heart disease.¹⁶ We have shown that this is because ¹⁸F-fluoride can highlight areas of microcalcification indicative of necrotic atheroma.²⁴ The ability to identify high risk or culprit plaque in the cephalic circulation has the potential to improve risk stratification in patients at high risk of stroke with a view to more targeted interventions. Our study aims were to compare and contrast the identification of clinically adjudicated culprit and high-risk plaque at the carotid bifurcation using ¹⁸F-fluoride and ¹⁸F-FDG PET/CT.

Methods

Patient Population

Two cohorts of people with a recent transient ischemic attack (TIA) or minor ischemic stroke were recruited: a case cohort with a high-grade internal carotid artery stenosis ($\geq 50\%$ by North American Symptomatic Carotid Endarterectomy Trial²⁵ criteria for men, $\geq 70\%$ for women) scheduled to undergo carotid endarterectomy and a control cohort in whom the cause of stroke was not attributed to carotid atheroma. Participants were recruited from outpatient clinics in National Health Service Lothian between January 2013 and June 2014 (for exclusion criteria, see Appendix in the [Data Supplement](#)). Research ethics committee approval (National Health Service West of Scotland Research Ethics Committee: 12/WS/0227) and the written and informed consent of all participants were obtained.

Baseline Assessment

Participants underwent clinical assessment at baseline including standard hematologic and biochemical indices. Serum C-reactive protein concentration was measured using the MULTIGENT CRP Vario assay on the high-throughput ARCHITECT system (Abbott Laboratories, Abbott Park, IL). Predicted cardiovascular risk was estimated using the ASSIGN score: a validated Scottish cardiovascular risk score that is similar to the Framingham risk score but includes additional factors, such as social deprivation and family history.²⁶

PET/CT Protocol

Static ¹⁸F-FDG PET/CT was acquired using a hybrid scanner (Biograph mCT, Siemens Medical Systems, Erlangen, Germany) 90 minutes after the intravenous administration of a target dose of 200 MBq. A rigid neck collar was fitted to minimize movement and standardize position. An attenuation-correction CT scan (nonenhanced, low dose 120 kV, 50 mAs) was then performed followed by PET acquisition covering 2 bed positions with the first upper bed centered over the carotid bifurcation in 3-dimensional mode for 20 minutes per bed. Patients were fasted for 6 hours before scanning.

¹⁸F-Fluoride PET/CT was undertaken the subsequent day 60 minutes after administering 250 MBq ¹⁸F-fluoride. A neck collar was

Table 1. Baseline Clinical Characteristics

	Stenosis Symptomatic	No Stenosis Symptomatic	P Value
n	18	8	
Age, y	71.7±12.3	66.1±12.5	0.30
Men, n (%)	12 (66.7)	4 (50)	0.67
BMI, kg·m ⁻²	26.2±5	27.3 (23.38–36)	0.40
Systolic blood pressure (mm Hg)	137±25	154±16	0.08
Diastolic blood pressure (mm Hg)	78±18	85±3.4	0.34
ASSIGN score	31±15.5	21.1±13.1	0.13
Presenting syndrome, n (%)			0.22
Stroke	8 (44)	6 (75)	
TIA/amaurosis fugax	10 (56)	2 (25)	
CEA side, right (%)	8 (44)		
Cardiovascular history, n (%)			
Coronary artery disease	10 (56)	2 (25)	0.22
Myocardial infarction	5 (28)	1 (13)	0.63
Risk factors, n (%)			
Hypertension	11 (61)	7 (88)	0.36
Diabetes	1 (6)	0	1
Hypercholesterolemia	13 (72)	5 (63)	0.67
Current smoker	6 (33)	2 (25)	0.67
Medication, n (%)			
Single antiplatelet therapy	14 (78)	6 (88)	1
Dual antiplatelet therapy	3 (17)	0	0.53
Anticoagulant	1 (6)	2 (25)	0.22
Statin	17 (94)	6 (75)	0.22
ACEi/AlIRB	7 (39)	2 (25)	0.20
Beta-antagonist	7 (39)	(131)	0.36
Calcium antagonist	7 (39)	2 (25)	0.67
Other antihypertensive	6 (39)	3 (38)	1
Hematology			
Hemoglobin, g/L	139.8±19	142.6±12.3	0.71
White cell count, ×10 ⁹ /L	8±1.4	6.4 (3.8–7.9)	0.06
Platelet count, ×10 ⁹ /L	259±64	273±63	0.60
Biochemistry			
Creatinine, mmol/L	88.5 (78–97.5)	76.8±13.5	0.07
Total cholesterol, mg/dL	117.9±34.8	181.7±54.1	0.81
C-reactive protein, mg/L*	3.1±2.6	2.4±3.5	0.66

Parametric data presented as mean±SD. Nonparametric data presented as median (IQR). Categorical data presented as number (%). ACE indicates angiotensin converting enzyme; AlIRB, angiotensin 2 receptor antagonists; BMI, body mass index; CAD, coronary artery disease; CEA, carotid endarterectomy; IQR, interquartile range; and transient ischemic attack.

*C-reactive protein values > 10 excluded as per AHA guidelines.




Figure 1. ^{18}F -Fluoride and ^{18}F -fluorodeoxyglucose (FDG) positron emission tomography of carotid arteries. Example of ^{18}F -fluoride (A, B, C) and ^{18}F -FDG (D, E, F) positron emission tomography (PET)/computed tomography (CT) of 1 patient before surgery for symptomatic carotid stenosis. A, ^{18}F -Fluoride PET axial slice. B, Registered CT angiogram axial slice. C, Fused PET/CT image. White arrow, Ruptured plaque showing ^{18}F -fluoride uptake. D–F, Same slice but with ^{18}F -FDG. Culprit shows uptake, but the contralateral side is obscured by uptake in the right longus colli (green star). An oblique computed tomography carotid angiogram reformat of the culprit (G). The operative specimen (H).

fitted and an attenuation-correction CT scan was performed. This was followed by PET acquisition covering 2 similar bed positions to the ^{18}F -FDG scan allowing 15 minutes per bed. A subset of 5 patients underwent fully dynamic ^{18}F -fluoride PET/CT with pharmacokinetic analysis as described previously.²⁴ Dynamic PET provides a quantitative assessment of uptake and these data were used to validate the semiquantitative static imaging data.

After PET acquisition, a CT carotid angiogram was performed without moving the subject (Care Dose 4D, 120 kV, 145 mA, rotation time 0.5 seconds, pitch 0.8. Contrast: 50 mL Niopam 370).

Static PET data were reconstructed using the Siemens UltraHD algorithm: ordered subset expectation maximization+point spread function modeling+time-of-flight; 2 iterations and 21 subsets; matrix size 200×200; 5 mm full-width half-maximum Gaussian smoothing. Dynamic PET data were similarly reconstructed but only using coincident events from the 60- to 75-minute time-bin. Dynamic data were analyzed as reported previously²⁴ and a K_i value was calculated using Patlak analysis.^{27,28}

Tissue Collection, Micro PET/CT, and Histology

At the time of endarterectomy, plaques were collected immediately after excision, photographed, and snap frozen. A random selection (n=8) of specimens was analyzed by micro PET/CT and histology to explore ^{18}F -fluoride binding patterns (see Appendix in the [Data Supplement](#) for detailed methods).

Image Analysis

Positron Emission Tomography/Computed Tomography

Static analysis of ^{18}F -FDG and ^{18}F -fluoride uptake was performed on an OsiriX workstation (OsiriX version 3.5.1 64-bit; OsiriX Imaging Software, Geneva, Switzerland). PET/CT data were reviewed alongside the CT angiogram. Scans were qualitatively assessed for registration, image quality, patient movement, and visual evidence of radiotracer uptake. PET and CT data were individually and carefully manually coregistered by lining up fiducial markers

apparent on both modalities (eg, cervical spine, mandible and hyoid on ^{18}F -fluoride imaging; skin, spinal cord, and brain on ^{18}F -FDG imaging). No formal inter-PET registration was performed. Three regions of interests (ROIs) were drawn on the carotid of interest on adjacent 3-mm axial slices. If a plaque was present, the ROIs were centered on the area of highest uptake. If there was no plaque, the uptake in the proximal 1 cm of internal carotid artery, just distal to the bifurcation was quantified. From these, standardized uptake values (SUVs; maximum, mean maximum, and mean) were recorded. Blood pool activity was determined from the average of 5 ROIs within the lumen of the superior vena cava to calculate target to background ratios.

Uptake in the proximal left common carotid artery was quantified to explore the relationships between arterial ^{18}F -FDG and ^{18}F -fluoride uptake in a site unaffected by an acute plaque event. Three ROIs were placed around this vessel and uptake was recorded.

Inter- and intraobserver reproducibility of ^{18}F -fluoride uptake measurements were determined using a random selection of 12 patients (24 carotids) by 2 experienced observers (A.T.V., G.S.) who were blinded to the clinical data during analysis.

Computed Tomography

The CT angiogram was assessed for image quality, plaque presence, location, and characteristics. Analysis was undertaken on a cardiovascular workstation (Vital Images, Minnetonka, MN). A blinded and experienced observer (A.V.) performed the semiautomated CT plaque analysis.

Statistical Analysis

Radiotracer uptake, expressed as mean and maximum SUV, was compared between the clinically adjudicated culprit carotid plaque and the contralateral side. Continuous variables are expressed as mean±standard deviation for normally distributed data and median (interquartile range) for skewed distributions. Skewed datasets underwent logarithmic transformation to normalize their distribution. Parametric (unpaired and paired *t*-tests) and nonparametric (Mann–Whitney *U* or Wilcoxon matched-pairs signed rank) tests were used for normally distributed and skewed data, respectively. Categorical




Figure 2. ¹⁸F-Fluoride micro positron emission tomography (PET)/computed tomography (CT), autoradiography, and alizarin red staining. Two examples of ex vivo ¹⁸F-fluoride micro PET/CT are shown (A–D, F). A, Coronal micro CT slice; B, corresponding micro PET; C, fused image; D, the plaque. Green arrow, Adherent thrombus over plaque rupture. Red arrow, Associated area of ¹⁸F-fluoride uptake (microcalcification). Black arrows, Areas of macrocalcification showing comparatively little uptake (A, C, F). These examples show that ¹⁸F-fluoride provides information of the presence of microcalcification and does not simply highlight all calcification. E, An example of micro CT slice registered to an alizarin red-stained section and the corresponding autoradiogram from a specimen that had been incubated whole in ¹⁸F-fluoride. It can be seen that the tracer is unable to penetrate the deeper layers of macrocalcification (black arrow), but is able to highlight microcalcification beyond the resolution of even micro CT (red arrow), thus explaining the findings in the micro PET/CT images.

data are presented as n (%) and were compared using Fisher's exact or Chi-squared tests. Correlation was undertaken with either Pearson's *r* or Spearman's ρ subject to the normality of the variables tested. To quantify inter- and intraobserver reproducibility of ¹⁸F-fluoride uptake measurement, the intraclass correlation coefficient was calculated and Bland-Altman analysis was undertaken.

Statistical analyses were performed with the use of SPSS version 18 (SPSS Inc, Chicago, IL) and Graph Pad Prism version 6.0 (GraphPad Software Inc, San Diego, CA). Statistical significance was defined as a 2-sided $P < 0.05$.

Results

Study Population

We recruited 26 patients: 18 in the carotid endarterectomy cohort and 8 in the control cohort (Figure I in the [Data Supplement](#)). Baseline characteristics (Table 1) were similar in both cohorts. Twenty patients completed all the imaging techniques (Figure 1). A minority did not receive all scans because of the technical and feasibility challenges of completing our multimodality imaging protocol in the very short time frame before surgery. Actual doses and uptake times are specified in Table I in the [Data Supplement](#). There were no adverse events during the study. There were 3 withdrawals.

Micro PET/CT and Histology

¹⁸F-Fluoride was observed to selectively highlight areas of pathologically high-risk microcalcification (Figure 2 and

Supplementary Movie I in the [Data Supplement](#)). Both on autoradiography and micro PET/CT, ¹⁸F-fluoride was observed to bind avidly to areas of microcalcification but only to the surface of large volume stable macrocalcifications. Our previous studies²⁴ would suggest that this was because of the inability of the fluoride ion to penetrate to the deeper layers of a large crystalline mass (with a low surface-area-to-volume ratio). In contradistinction, the powdery deposits of microcalcification (not visible on CT) provide a large area (high surface-area-to-volume ratio) for the fluoride ion to bind.

Imaging

When comparing the ¹⁸F-fluoride uptake on static imaging with full dynamic modeling, K_i was most strongly correlated with the SUV_{mean} ($r = 0.93$ [95% confidence interval 0.64–0.99], $P = 0.001$; Figure 3). There were no fixed or proportional biases in the SUV measurements within and between observers (Table II in the [Data Supplement](#)). These assessments also demonstrated high intraclass correlation coefficients (all > 0.90).

Assessment of Uptake: Culprit Compared With Contralateral and Controls

¹⁸F-Fluoride uptake was variably present in most plaques with all culprits showing uptake on visual assessment. In the large majority of patients undergoing carotid endarterectomy who were scanned (87%; 13/15), there was more visual uptake of ¹⁸F-fluoride in the culprit compared with the contralateral




Figure 3. Dynamic positron emission tomography (PET) acquisition and examples of ^{18}F -fluoride uptake. **A**, Correlation between statically derived standardized uptake value (SUV) and dynamically measured K_i (dotted line is 95% confidence interval). Photograph shows a dynamic PET study in process. **B**, **C**, ^{18}F -Fluoride uptake into areas of cerebral infarction. **D–F**, From 1 patient. **D**, Axial image from computed tomography carotid angiogram; **E**, Fused axial ^{18}F -fluoride PET/computed tomography (CT; white arrow, culprit plaque); **F**, Oblique reconstruction. **G–I**, Similar reconstructions from a different patient. **J**, Obliquely reformatted PET/CT image from a patient who developed a fatal stroke (ipsilateral to the lesion marked by a white arrow) 2 weeks after this scan. The contralateral side, which had shown minimal uptake, had been deemed the culprit based on duplex assessment.

side. In the 2 patients without discriminatory uptake, there was heavy uptake bilaterally but more ^{18}F -fluoride uptake on the contralateral side. One patient had grossly ossified carotids and the second, at the time of surgery, was found to have a fibrous stenosis (low signal side) and was subsequently admitted with a fatal ischemic stroke on the contralateral side (high signal side, Figure 3J). ^{18}F -Fluoride uptake was focal and readily identifiable with excellent signal to background discrimination. Spillover from the hyoid bone, thyroid cartilage and cervical vertebrae occasionally made drawing ROI difficult, but only 1 vessel was rendered uninterpretable. On SUV analysis, the clinically adjudicated culprit showed higher uptake than either the paired contralateral ($\log_{10}\text{SUV}_{\text{mean}} 0.29 \pm 0.10$ versus 0.23 ± 0.11 , $P=0.001$) or an unpaired control ($\log_{10}\text{SUV}_{\text{mean}} 0.29 \pm 0.10$ versus 0.12 ± 0.11 , $P=0.001$) irrespective of the method of quantification (Table 2 and Figures 3 and 4).

Of note, in patients with a stroke in whom the imaging extended to encompass the affected territory of the brain ($n=3$), intense ^{18}F -fluoride uptake was noted in regions of cerebral infarction ($\text{SUV}_{\text{mean}} 4.8 \pm 1.98$ versus SUV_{mean} of 0.07 ± 0.02 for

contralateral noninfarcted brain, $P<0.001$; Figure 3B and 3C, Movie II in the [Data Supplement](#)).

Seven of the 16 culprit carotid plaques demonstrated clear and discernible increased ^{18}F -FDG uptake. However, this uptake was generally more diffuse than ^{18}F -fluoride and analysis was more frequently hampered by overspill from sternocleidomastoid, longus colli, tonsillar tissue, and the submandibular salivary glands (Figure 1). This rendered 5 vessels noninterpretable. In the remaining 4 culprit vessels, no increase in ^{18}F -FDG uptake could be observed. Overall on semiquantitative analysis, ^{18}F -FDG uptake was not higher in the clinically adjudicated culprit compared with either the paired contralateral ($\text{SUV}_{\text{mean}} 1.83 \pm 0.55$ versus 1.81 ± 0.46 , $P=0.269$) or control vessels ($\text{SUV}_{\text{mean}} 1.83 \pm 0.55$ versus 2.08 ± 0.33 , $P=0.269$) irrespective of the method of quantification (Table 2 and Figure 4).

Uptake Compared With Plaque Features and Baseline Characteristics

^{18}F -Fluoride uptake was correlated with several plaque characteristics on CT plaque analysis (Table 3). The strongest

Table 2. Radiotracer Uptake: Comparative Data

	Culprit Vessel	Contralateral Vessel	P Value for Culprit vs Contralateral	Control	P Value for Culprit vs Control
¹⁸ F-Fluoride					
SUV _{max}	2.56 (2.35–3.54)	2.18 (1.94–3.01)	*	1.78 (1.55–2.22)	*
SUV _{meanmax}	2.42 (2.24–3.24)	1.97 (1.78–2.74)	*	1.67 (1.41–2.08)	*
SUV _{mean}	1.92 (1.71–2.46)	1.64 (1.39–1.98)	*	1.41 (1.10–1.53)	*
TBR _{max}	2.75 (2.39–3.21)	2.42 (2.02–2.82)	*	2.44 (1.715–2.48)	*
TBR _{meanmax}	2.61 (2.24–2.90)	2.32 (1.74–2.58)	*	2.29 (1.61–2.37)	*
TBR _{mean}	1.96 (1.62–2.22)	1.71 (1.38–1.86)	*	1.67 (1.28–1.95)	*
Log ₁₀ SUV _{max}	0.44±0.14	0.38±0.16	0.013	0.25±0.09	<0.001
Log ₁₀ SUV _{meanmax}	0.42±0.13	0.34±0.15	0.005	0.22±0.10	<0.001
Log ₁₀ SUV _{mean}	0.29±0.10	0.23±0.11	0.001	0.12±0.11	<0.001
Log ₁₀ TBR _{max}	0.45±0.13	0.39±0.13	0.014	0.31±0.15	0.016
Log ₁₀ TBR _{meanmax}	0.43±0.13	0.35±0.12	0.005	0.28±0.15	0.014
Log ₁₀ TBR _{mean}	0.30±0.12	0.24±0.11	0.001	0.18±0.13	0.029
¹⁸ F-FDG					
SUV _{max}	2.32±0.78	2.32±0.77	0.675	2.61±0.53	0.375
SUV _{meanmax}	2.21±0.72	2.24±0.74	0.755	2.51±0.46	0.317
SUV _{mean}	1.83±0.55	1.81±0.46	0.346	2.08±0.33	0.269
TBR _{max}	1.88±0.31	1.81±0.31	0.496	1.86±0.27	0.848
TBR _{meanmax}	1.80±0.29	1.74±0.29	0.554	1.79±0.20	0.925
TBR _{mean}	1.49±0.19	1.44±0.19	0.358	1.48±0.10	0.922

Parametric data presented as mean±SD. Nonparametric data presented as median (IQR). FDG indicates fluorodeoxyglucose; SUV, standardized uptake value; TBR, target to background ratio; and IQR, interquartile range.

*Statistical testing performed on the normalized log₁₀ transformed data.

correlation was with the Agatston score (SUV_{mean} $r=0.72$, $P<0.001$), although there were also strong correlations with high-risk features such as plaque burden (SUV_{mean} $r=0.51$, $P=0.003$) and positive remodeling (wall-distal internal carotid artery lumen ratio, with SUV_{mean} $r=0.53$, $P=0.003$).

In terms of baseline cardiovascular risk indices, uptake of both tracers in the vasculature correlated with age (¹⁸F-FDG SUV_{meanmax} $r=0.48$, $P=0.037$; ¹⁸F-fluoride SUV_{mean} $r=0.59$, $P=0.007$) and the cardiovascular risk score (¹⁸F-FDG SUV_{meanmax} $r=0.53$, $P=0.019$; ¹⁸F-fluoride SUV_{mean} $r=0.65$, $P=0.002$) but neither was associated with serum C-reactive protein concentration.

Discussion

We have shown that the culprit plaques of patients with recent TIA or minor ischemic strokes enhance with ¹⁸F-fluoride on PET/CT. Uptake was focal, readily identifiable, and discriminated between culprit and nonculprit. ¹⁸F-Fluoride uptake was associated with high-risk plaque phenotype and predicted cardiovascular risk. In contrast, while ¹⁸F-FDG uptake was present in plaque and correlated with cardiovascular risk, it was more diffuse and prone to spillover and therefore less discriminatory. ¹⁸F-FDG also failed to correlate with established high-risk plaque morphological features.

We have previously shown that ¹⁸F-fluoride uptake is associated with increased intraplaque markers of cell death, procalcific proteins, inflammation, and high-risk features in the coronary circulation in vivo and the carotid system ex vivo.¹⁶ Here, we confirm our previous observations²⁴ (which we have also recently reviewed²⁹) that this is explained by the ability of ¹⁸F-fluoride to report microcalcification. Why is this the case? Far from a passive and degenerative process, vessel mineralization is a controlled response to a variety of insults, particularly oxidized inflammatory lipid (as in the calcific response to tuberculosis infection where lipid-rich bacterial cell walls become oxidized through leukocyte action). It is therefore perhaps no surprise that direct links between atherosclerosis and the induction of extraskelatal osteogenesis have been identified.^{30,31} The presence of cellular necrosis and apoptosis³² is also likely to potentiate this relationship further. Hydroxyapatite nanocrystals themselves may also further drive the inflammatory cycle by setting up a positive feedback loop of increasing calcification, increasing inflammation, and increasing cell death.³⁰ Furthermore, by accumulating in the surface of thin fibrous caps, microcalcifications may focally increase mechanical stress and thus promote structural cap failure and plaque rupture.^{7,33,34} ¹⁸F-Fluoride can demonstrate this pathologically important microscopic calcific response.




Figure 4. ¹⁸F-Fluoride and ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography uptake. Dynamic PET acquisition and examples of ¹⁸F-fluoride uptake. Uptake in clinically adjudicated culprit vs contralateral and vs controls. Tukey box and whisker plots. **A, B,** ¹⁸F-Fluoride uptake into culprit (red) and contralateral (blue) plaque using the standardized uptake value (SUV_{mean}) and target to background ratio (TBR)_{mean} measurements, respectively. **C, D,** Each demonstrate comparison in ¹⁸F-fluoride uptake between carotid endarterectomy (CEA) patients (red) and controls (blue); uptake is reported by SUV_{mean} in **C** and TBR_{mean} in **D**. **E–H,** The same comparisons but using ¹⁸F-FDG.

This is the first observation of ¹⁸F-fluoride uptake in necrotic brain tissue and merits consideration. Uptake of this and other bone metabolism markers has previously been observed in tissue necrosis.^{33,35} This is likely to be because of cell membrane disruption with influx of calcium and formation of nanoscale calcium phosphate complexes. These offer a substrate to which ¹⁸F-fluoride can adsorb, allowing us to visualize the microcalcification associated with necrosis. We have also observed the same process in myocardial tissue postinfarction (Figure II in the [Data Supplement](#)).

We confirmed identification of culprit plaque in 2 ways. First, we compared the culprit to the ideal internal control, the contralateral carotid artery (which is almost invariably diseased). Second, we compared the culprit against a valid external control; patients with a TIA or minor ischemic stroke not attributed to carotid plaque. This shows that ¹⁸F-fluoride may have real potential in helping to identify culprit plaque thus helping decision-making. This is exemplified by the case where a plaque with high uptake deemed nonculprit subsequently caused a fatal ischemic stroke.

We compared uptake of ¹⁸F-fluoride with ¹⁸F-FDG. Unlike ¹⁸F-fluoride, overall, ¹⁸F-FDG uptake was not significantly higher in culprit lesions. Moreover, on a per-lesion basis, ¹⁸F-FDG failed to correlate with high-risk plaque morphological features, whereas ¹⁸F-fluoride uptake correlated with plaque burden, positive remodeling, and luminal stenosis: all established markers of plaque risk. Other studies have explored the utility of ¹⁸F-FDG alone in carotid atherosclerosis^{9–11,14,36–39} and a few have directly compared clinical culprit with nonculprit plaques.^{8,12,13} Our results are consistent with these previous findings with significant uptake noted in some but not all culprit plaques, in part because of spillover from adjacent muscle. Our observations are also influenced by the ubiquity of statin therapy, potentially blunting ¹⁸F-FDG uptake. We did, however, note that proximal carotid uptake correlated with cardiovascular risk indicating that ¹⁸F-FDG does reflect a major aspect of vessel pathobiology. As others suggest,^{38,40} it may be that ¹⁸F-FDG better reflects generalized vascular inflammation and that the relationship between the tracer and a single advanced and acute plaque is more complicated. There are increasing data available concerning other more specific markers of inflammation, such as those targeting the macrophage-specific somatostatin receptor.⁴¹ These will theoretically be less hampered by overspill.

Our findings confirm those of a smaller study of 9 patients by Quirce et al²³ that explored ¹⁸F-fluoride and ¹⁸F-FDG uptake in symptomatic patients. They showed that ¹⁸F-fluoride uptake appeared to be higher in the symptomatic carotid and that ¹⁸F-FDG uptake was nondiscriminatory. Taken together with our current larger series, this suggests that ¹⁸F-fluoride has the potential to be a useful and robust clinical tool to identify culprit atherosclerotic plaque. Vascular ¹⁸F-fluoride imaging could therefore guide clinical management better than the current standard of care, and lead to trials of plaque-specific interventions that go beyond simple assessments of anatomic luminal stenosis severity.

Limitations

This was a small pilot observational study (recruitment is very challenging given the time pressure to intervene) and

Table 3. Plaque Analysis by CT and PET

		All Patients
Calcium score		
Patients with AC CT usable for calcium score		24
Carotid bifurcations analyzed for calcium score		48
Agatston score, AU		164 (5–494)
Log ₁₀ Agatston score		1.76±1.13
Calcium volume, mm ³		150 (15.75–404)
CT plaque analysis		
Patients with analyzable CT angiogram		17
Internal carotid artery plaques analyzed		33
CT diameter stenosis, %		50 (0–77)
Wall-distal ICA lumen ratio, %		90 (54–173)
Plaque burden, %		49.4±16.4
Lipid/necrosis volume, mm ³		37.5 (8.6–79.5)
Lipid/necrosis % volume		6.7 (2.4–15.8)
Fibrofatty volume, mm ³		201 (96–313)
Fibrofatty % volume		42.8±15.6
Calcium volume, mm ³		211 (124–358)
Calcium % volume		47.4±20.8
¹⁸ F-Fluoride PET SUV _{mean}		1.69 (1.40–2.04)
	<i>r</i>	<i>P</i> Value
vs CT Agatston score	0.79	<0.001
vs CT diameter stenosis	0.54	0.002
vs plaque burden	0.51	0.004
vs wall-distal ICA lumen ratio	0.53	0.003
vs lipid/necrosis volume	0.32	0.080
vs fibrofatty volume	0.29	0.126
vs calcium volume	0.72	<0.001
¹⁸ F-FDG PET SUV _{mean}		1.92±0.46
	<i>r</i>	<i>P</i> Value
vs CT Agatston score	–0.14	0.469
vs CT diameter stenosis	–0.10	0.620
vs plaque burden	–0.03	0.873
vs wall-distal ICA lumen ratio	0.00	0.996
vs lipid/necrosis volume	–0.19	0.315
vs fibrofatty volume	–0.15	0.457
vs calcium volume	0.01	0.918

Parametric data presented as mean±SD. Nonparametric data presented as median (IQR). AC indicates attenuation correction; AU, arbitrary units; CT, computed tomography; FDG, fluorodeoxyglucose; ICA, internal carotid artery; IQR, interquartile range; PET, positron emission tomography; and SUV, standardized uptake value.

findings should be regarded as preliminary. The true utility of ¹⁸F-fluoride PET/CT will need to be evaluated by prospective studies with patients randomized to intervention based on imaging. ¹⁸F-Fluoride PET/CT will need to be

compared with other techniques⁴² (in particular MR or PET/MR) which have the advantages of improved soft tissue definition, reduced radiation, and lack of iodinated contrast. We did not perform prolonged-delayed ¹⁸F-FDG imaging which some authors have suggested is advantageous.⁴³ We also acknowledge that quantitative vascular PET has some potential limitations because of the partial volume effects of small vascular structures. Finally, as vascular ¹⁸F-fluoride imaging is developed, consideration must be given to harmonizing acquisition and reconstruction protocols,⁴⁴ as well as achieving consensus on the uptake parameter of choice (SUV versus target to background ratio versus volumetric parameters⁴⁵) and whether to use manual or automated methods to define ROI. This will reduce variation between scanners and research groups and permit meaningful multicenter studies.

Conclusion

We have shown that ¹⁸F-fluoride PET/CT is able to identify culprit or high-risk carotid plaque. In comparison, ¹⁸F-FDG, the most widely used tracer in cardiovascular PET imaging, did not reliably identify culprit plaque and did not correlate with high-risk morphological features. ¹⁸F-Fluoride PET has major potential to improve how we assess and manage the risk of stroke in patients with atherosclerosis.

Acknowledgments

We acknowledge the help and support of the vascular surgical staff at the Royal Infirmary of Edinburgh and the radiography and radiochemistry staff of the Clinical Research Imaging Centre.

Sources of Funding

Dr Vesey and the study were funded by program grants from the British Heart Foundation (PG12/8/29371) and Chest Heart and Stroke Scotland (R13/A147). Dr Jenkins, Vesey, Dweck, and Newby are supported by the British Heart Foundation (FS/14/78/31020, CH/09/002) and the Wellcome Trust (WT103782A1A). Dr Dweck is the recipient of the Sir Jules Thorn Biomedical Research Award 2015. The Wellcome Trust Clinical Research Facility and the Clinical Research Imaging Centre are supported by National Health Service (NHS) Research Scotland (NRS) through NHS Lothian. Dr Beek is supported by the Scottish Imaging Network—a Platform of Scientific Excellence (SINAPSE). Dr Rudd is part-supported by the National Institute for Health Research Cambridge Biomedical Research Centre, the British Heart Foundation, and the Wellcome Trust.

Disclosures

None.

References

- Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, Warlow CP, Barnett HJ; Carotid Endarterectomy Trialists' Collaboration. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. *Lancet*. 2003;361:107–116.
- Rerkasem K, Rothwell PM. Carotid endarterectomy for symptomatic carotid stenosis. *Cochrane Database Syst Rev* 2011; CD001081.
- Chambers BR, Donnan GA. Carotid endarterectomy for asymptomatic carotid stenosis. *Cochrane Database Syst Rev* 2005; CD001923.
- Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med*. 2011;364:226–235. doi: 10.1056/NEJMoa1002358.
- Libby P. Inflammation in atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2012;32:2045–2051. doi: 10.1161/ATVBAHA.108.179705.
- Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. *N Engl J Med*. 2013;368:2004–2013. doi: 10.1056/NEJMra1216063.
- Ewence AE, Bootman M, Roderick HL, Skepper JN, McCarthy G, Epple M, Neumann M, Shanahan CM, Proudfoot D. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. *Circ Res*. 2008;103:e28–e34. doi: 10.1161/CIRCRESAHA.108.181305.
- Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnström P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [¹⁸F]-fluorodeoxyglucose positron emission tomography. *Circulation*. 2002;105:2708–2711.
- Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, Yates D, LaMuraglia GM, Furie K, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. *In vivo* ¹⁸F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. *J Am Coll Cardiol*. 2006;48:1818–1824. doi: 10.1016/j.jacc.2006.05.076.
- Tawakol A, Migrino RQ, Hoffmann U, Abbara S, Houser S, Gewirtz H, Muller JE, Brady TJ, Fischman AJ. Noninvasive *in vivo* measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. *J Nucl Cardiol*. 2005;12:294–301.
- Fayad ZA, Mani V, Woodward M, Kallend D, Bansilal S, Pozza J, Burgess T, Fuster V, Rudd JH, Tawakol A, Farkouh ME. Rationale and design of DALPLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography. *Am Heart J*. 2011;162:214–221.e2. doi: 10.1016/j.ahj.2011.05.006.
- Davies JR, Rudd JH, Fryer TD, Graves MJ, Clark JC, Kirkpatrick PJ, Gillard JH, Warburton EA, Weissberg PL. Identification of culprit lesions after transient ischemic attack by combined ¹⁸F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. *Stroke*. 2005;36:2642–2647. doi: 10.1161/01.STR.0000190896.67743.b1.
- Marnane M, Merwick A, Sheehan OC, Hannon N, Foran P, Grant T, Dolan E, Moroney J, Murphy S, O'Rourke K, O'Malley K, O'Donohoe M, McDonnell C, Noone I, Barry M, Crowe M, Kavanagh E, O'Connell M, Kelly PJ. Carotid plaque inflammation on ¹⁸F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. *Ann Neurol*. 2012;71:709–718. doi: 10.1002/ana.23553.
- Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, Hayabuchi N, Imaizumi T. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. *J Am Coll Cardiol*. 2006;48:1825–1831. doi: 10.1016/j.jacc.2006.03.069.
- Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, Richardson H, White A, McKillop G, van Beek EJ, Boon NA, Rudd JH, Newby DE. Coronary arterial ¹⁸F-sodium fluoride uptake: a novel marker of plaque biology. *J Am Coll Cardiol*. 2012;59:1539–1548. doi: 10.1016/j.jacc.2011.12.037.
- Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, Yeoh SE, Wallace W, Salter D, Fletcher AM, van Beek EJ, Flapan AD, Uren NG, Behan MW, Cruden NL, Mills NL, Fox KA, Rudd JH, Dweck MR, Newby DE. ¹⁸F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. *Lancet*. 2014;383:705–713. doi: 10.1016/S0140-6736(13)61754-7.
- Dweck MR, Jones C, Joshi NV, Fletcher AM, Richardson H, White A, Marsden M, Pessotto R, Clark JC, Wallace WA, Salter DM, McKillop G, van Beek EJ, Boon NA, Rudd JH, Newby DE. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. *Circulation*. 2012;125:76–86. doi: 10.1161/CIRCULATIONAHA.111.051052.
- Dweck MR, Jenkins WS, Vesey AT, Pringle MA, Chin CW, Malley TS, Cowie WJ, Tsampasian V, Richardson H, Fletcher A, Wallace WA, Pessotto R, van Beek EJ, Boon NA, Rudd JH, Newby DE. ¹⁸F-sodium fluoride uptake is a marker of active calcification and disease progression in patients with aortic stenosis. *Circ Cardiovasc Imaging*. 2014;7:371–378. doi: 10.1161/CIRCIMAGING.113.001508.
- Beheshti M, Saboury B, Mehta NN, Torigian DA, Werner T, Mohler E, Wilensky R, Newberg AB, Basu S, Langsteger W, Alavi A. Detection and global quantification of cardiovascular molecular calcification by fluoro-¹⁸-fluoride positron emission tomography/computed tomography—a novel concept. *Hell J Nucl Med*. 2011;14:114–120.
- Hyafil F, Messika-Zeitoun D, Burg S, Rouzet F, Benali K, Iung B, Vahanian A, Le Guludec D. Detection of ¹⁸fluoride sodium accumulation

- by positron emission tomography in calcified stenotic aortic valves. *Am J Cardiol.* 2012;109:1194–1196. doi: 10.1016/j.amjcard.2011.11.060.
21. Li Y, Berenji GR, Shaba WF, Tafti B, Yevdayev E, Dadparvar S. Association of vascular fluoride uptake with vascular calcification and coronary artery disease. *Nucl Med Commun.* 2012;33:14–20. doi: 10.1097/MNM.0b013e32834c187e.
 22. Quirce R, Martínez-Rodríguez I, De Arcocha Torres M, Jiménez-Bonilla JF, Banzo I, Rebollo M, Revilla MA, Palacio E, Rubio-Vassallo A, Ortega-Nava F, Del Castillo-Matos R, Carril JM. Contribution of ¹⁸F-sodium fluoride PET/CT to the study of the carotid atheroma calcification. *Rev Esp Med Nucl Imagen Mol.* 2013;32:22–25. doi: 10.1016/j.rem.2012.08.003.
 23. Quirce R, Martínez-Rodríguez I, Banzo I, Jiménez-Bonilla J, Martínez-Amador N, Ibáñez-Bravo S, López-Defilló J, Jiménez-Alonso M, Revilla MA, Carril JM. New insight of functional molecular imaging into the atheroma biology: ¹⁸F-NaF and ¹⁸F-FDG in symptomatic and asymptomatic carotid plaques after recent CVA. Preliminary results. *Clin Physiol Funct Imaging.* 2016;36:499–503. doi: 10.1111/cpf.12254.
 24. Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, Joshi FR, Gallagher FA, Warburton EA, Bennett MR, Brindle KM, Newby DE, Rudd JH, Davenport AP. Identifying active vascular microcalcification by (¹⁸F)-sodium fluoride positron emission tomography. *Nat Commun.* 2015;6:7495. doi: 10.1038/ncomms8495.
 25. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. *N Engl J Med.* 1991;325:445–453.
 26. de la Iglesia B, Potter JF, Poulter NR, Robins MM, Skinner J. Performance of the ASSIGN cardiovascular disease risk score on a UK cohort of patients from general practice. *Heart.* 2011;97:491–499. doi: 10.1136/hrt.2010.203364.
 27. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. *J Cereb Blood Flow Metab.* 1983;3:1–7. doi: 10.1038/jcbfm.1983.1.
 28. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. *J Cereb Blood Flow Metab.* 1985;5:584–590. doi: 10.1038/jcbfm.1985.87.
 29. Dweck MR, Aikawa E, Newby DE, Tarkin JM, Rudd JH, Narula J, Fayad ZA. Noninvasive molecular imaging of disease activity in atherosclerosis. *Circ Res.* 2016;119:330–340. doi: 10.1161/CIRCRESAHA.116.307971.
 30. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. *Nat Rev Cardiol.* 2010;7:528–536. doi: 10.1038/nrcardio.2010.115.
 31. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, Jaffer FA, Aikawa M, Weissleder R. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging *in vivo*. *Circulation.* 2007;116:2841–2850. doi: 10.1161/CIRCULATIONAHA.107.732867.
 32. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification *in vitro*: evidence for initiation of vascular calcification by apoptotic bodies. *Circ Res.* 2000;87:1055–1062.
 33. Maldonado N, Kelly-Arnold A, Vengrenyuk Y, Laudier D, Fallon JT, Virmani R, Cardoso L, Weinbaum S. A mechanistic analysis of the role of microcalcifications in atherosclerotic plaque stability: potential implications for plaque rupture. *Am J Physiol Heart Circ Physiol.* 2012;303:H619–H628. doi: 10.1152/ajpheart.00036.2012.
 34. Bobryshev YV, Killingsworth MC, Lord RS, Grabs AJ. Matrix vesicles in the fibrous cap of atherosclerotic plaque: possible contribution to plaque rupture. *J Cell Mol Med.* 2008;12:2073–2082. doi: 10.1111/j.1582-4934.2008.00230.x.
 35. Wang Y-F, Lin T-K, Chuang M-H. Myocardial infarction: an incidental finding on bone scintigraphy. *Tzu Chi Med J.* 2002;14:49–53.
 36. Graebe M, Pedersen SF, Borgwardt L, Højgaard L, Sillesen H, Kjaer A. Molecular pathology in vulnerable carotid plaques: correlation with [¹⁸]-fluorodeoxyglucose positron emission tomography (FDG-PET). *Eur J Vasc Endovasc Surg.* 2009;37:714–721. doi: 10.1016/j.ejvs.2008.11.018.
 37. Pedersen SF, Graebe M, Fisker Hag AM, Højgaard L, Sillesen H, Kjaer A. Gene expression and ¹⁸FDG uptake in atherosclerotic carotid plaques. *Nucl Med Commun.* 2010;31:423–429. doi: 10.1097/MNM.0b013e32833767e0.
 38. Moustafa RR, Izquierdo-Garcia D, Fryer TD, Graves MJ, Rudd JH, Gillard JH, Weissberg PL, Baron JC, Warburton EA. Carotid plaque inflammation is associated with cerebral microembolism in patients with recent transient ischemic attack or stroke: a pilot study. *Circ Cardiovasc Imaging.* 2010;3:536–541. doi: 10.1161/CIRCIMAGING.110.938225.
 39. Figueroa AL, Subramanian SS, Cury RC, Truong QA, Gardecki JA, Tearney GJ, Hoffmann U, Brady TJ, Tawakol A. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. *Circ Cardiovasc Imaging.* 2012;5:69–77. doi: 10.1161/CIRCIMAGING.110.959478.
 40. Joshi F, Rosenbaum D, Bordes S, Rudd JH. Vascular imaging with positron emission tomography. *J Intern Med.* 2011;270:99–109. doi: 10.1111/j.1365-2796.2011.02392.x.
 41. Pedersen SF, Sandholt BV, Keller SH, Hansen AE, Clemmensen AE, Sillesen H, Højgaard L, Ripa RS, Kjaer A. ⁶⁴Cu-DOTATATE PET/MRI for detection of activated macrophages in carotid atherosclerotic plaques: studies in patients undergoing endarterectomy. *Arterioscler Thromb Vasc Biol.* 2015;35:1696–1703. doi: 10.1161/ATVBAHA.114.305067.
 42. Naylor AR, Sillesen H, Schroeder TV. Clinical and imaging features associated with an increased risk of early and late stroke in patients with symptomatic carotid disease. *Eur J Vasc Endovasc Surg.* 2015;1–11.
 43. Blomberg BA, Akers SR, Saboury B, Mehta NN, Cheng G, Torigian DA, Lim E, Del Bello C, Werner TJ, Alavi A. Delayed time-point ¹⁸F-FDG PET CT imaging enhances assessment of atherosclerotic plaque inflammation. *Nucl Med Commun.* 2013;34:860–867. doi: 10.1097/MNM.0b013e3283637512.
 44. Huet P, Burg S, Le Guludec D, Hyafil F, Buvat I. Variability and uncertainty of ¹⁸F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement. *J Nucl Med.* 2015;56:552–559. doi: 10.2967/jnumed.114.142596.
 45. Mehta NN, Torigian DA, Gelfand JM, Saboury B, Alavi A. Quantification of atherosclerotic plaque activity and vascular inflammation using [¹⁸-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). *J Vis Exp.* 2012:e3777–e3777.

CLINICAL PERSPECTIVE

Stroke remains the leading global cause of disability and is responsible for huge healthcare costs. It is commonly caused by thromboembolism from extracranial atherosclerotic plaque. In addition to medical therapy, invasive carotid artery intervention (by endarterectomy or stenting) has a role in reducing the chances of subsequent stroke. However, intervention itself is associated with significant risk and the decision to proceed with surgery is still based principally on stenosis severity, an outdated parameter. This report shows that by selectively demonstrating intraplaque microcalcification, a pathologically high-risk process that reflects ongoing inflammation and cell death, ¹⁸F-fluoride PET/CT may be able to identify plaque at particular risk of causing future stroke. The technique, as part of a multimodal risk stratification strategy, may help to ensure the appropriate planning of surgical intervention. This would potentially avoid unnecessary surgery on quiescent yet tightly stenosed plaques and conversely permit the identification and removal of high-risk plaques that currently do not meet criteria for intervention. ¹⁸F-Fluoride PET/CT also offers the possibility of noninvasively assessing the response to existing or novel pharmacological agents permitting the personalization of therapy to maximize benefit and minimize risk of complications.